Organovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Organovo (NASDAQ:ONVOGet Rating) in a research report issued on Monday. The firm set a “sell” rating on the medical research company’s stock.

Shares of ONVO stock opened at $2.34 on Monday. The stock has a market capitalization of $20.37 million, a PE ratio of -1.68 and a beta of 0.64. Organovo has a 1-year low of $2.24 and a 1-year high of $9.89. The business has a 50-day moving average of $2.92 and a 200 day moving average of $3.46.

Hedge funds have recently modified their holdings of the stock. Millennium Management LLC purchased a new stake in Organovo during the 3rd quarter valued at about $94,000. Susquehanna International Group LLP boosted its holdings in Organovo by 30.9% during the 4th quarter. Susquehanna International Group LLP now owns 19,766 shares of the medical research company’s stock valued at $72,000 after acquiring an additional 4,666 shares during the period. Moors & Cabot Inc. purchased a new stake in Organovo during the 3rd quarter valued at about $27,000. Morgan Stanley boosted its holdings in Organovo by 78.5% during the 1st quarter. Morgan Stanley now owns 27,211 shares of the medical research company’s stock valued at $262,000 after acquiring an additional 11,968 shares during the period. Finally, Prescott Group Capital Management L.L.C. purchased a new stake in Organovo during the 4th quarter valued at about $200,000. Institutional investors own 26.03% of the company’s stock.

Organovo Company Profile (Get Rating)

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.

Read More

Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.